自身抗体阳性是肺癌化疗引起间质性肺炎恶化的危险因素。
Autoantibody Positivity Is a Risk Factor for Chemotherapy-induced Exacerbation of Interstitial Pneumonia in Lung Cancer.
机构信息
Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.
Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan;
出版信息
Anticancer Res. 2021 Mar;41(3):1497-1506. doi: 10.21873/anticanres.14908.
BACKGROUND
No study has yet investigated the incidence of chemotherapy-induced acute exacerbation of interstitial pneumonia (AE-IP) in patients with autoantibody-positive IP and lung cancer. Herein, we retrospectively compared the incidence of chemotherapy-induced AE-IP in patients with lung cancer between those with autoantibody-positive and -negative IP.
PATIENTS AND METHODS
Between October 2003 and December 2018, patients with lung cancer who received chemotherapy, underwent serological test of antinuclear antibody or rheumatoid factor, and were diagnosed with IP were enrolled.
RESULTS
A total of 81 patients were enrolled; autoantibody-positive cases were observed in 23.5%. Autoantibody positivity was an independent risk factor for chemotherapy-induced AE-IP at 6 months after initiation of chemotherapy for lung cancer. The time to onset of AE-IP was significantly shorter in autoantibody-positive patients than in the seronegative patients.
CONCLUSION
Chemotherapy-induced AE-IP developed earlier in patients with autoantibody than in those without. Therefore, the potential development of AE-IP in autoantibody-positive patients warrants monitoring.
背景
尚无研究调查自身抗体阳性间质性肺病（IP）合并肺癌患者化疗诱导的间质性肺炎急性加重（AE-IP）的发生率。在此，我们回顾性比较了自身抗体阳性和阴性 IP 合并肺癌患者化疗诱导的 AE-IP 发生率。
患者与方法
2003 年 10 月至 2018 年 12 月，纳入接受化疗、行抗核抗体或类风湿因子血清学检测、并诊断为 IP 的肺癌患者。
结果
共纳入 81 例患者；自身抗体阳性者占 23.5%。自身抗体阳性是肺癌化疗开始后 6 个月发生 AE-IP 的独立危险因素。与血清阴性患者相比，自身抗体阳性患者 AE-IP 的发病时间明显更早。
结论
与无自身抗体者相比，自身抗体阳性者的 AE-IP 更早出现。因此，需要监测自身抗体阳性患者 AE-IP 的潜在发展。
Zotero 插件